Core Viewpoint - Pfizer's stock has significantly declined, presenting a potential buying opportunity despite underlying challenges [2][3][7] Company Challenges - Pfizer's stock decline is primarily due to rapidly decreasing sales of COVID-19 products, compounded by vaccine skepticism and reduced pandemic concerns [3] - The company faced setbacks with product withdrawals, including the sickle cell disease therapy Oxbryta and the oral obesity drug danuglipron due to safety concerns [4] - Patent expirations for key drugs, such as Inlyta, Xeljanz, and Eliquis, are imminent, which could impact revenue [5] - Potential regulatory challenges from the Trump administration, including tariffs and international reference pricing, add to the uncertainty [6][12] Market Sentiment - Despite the challenges, there is a level of optimism among analysts, with 8 out of 25 rating Pfizer as a buy or strong buy, and an average 12-month price target indicating a 28% upside potential [7] - Pfizer's reliance on COVID-19 product sales has decreased, with these products accounting for less than 7.7% of total revenue in Q1 2025 [8] Growth Prospects - Pfizer is exploring patent term extensions and has several promising products in its pipeline that could offset revenue losses from expiring patents [9] - The company is actively seeking business development opportunities, including licensing agreements and potential acquisitions to enhance its product offerings [11] Financial Metrics - Pfizer's shares are trading at over 8 times forward earnings, with a low price-to-earnings-to-growth (PEG) ratio of 0.6, indicating attractive valuation relative to growth prospects [14] - The forward dividend yield stands at 7.47%, and despite a high payout ratio of 122.5%, Pfizer has sufficient free cash flow and anticipates $7.2 billion in cost savings by 2027 [15] Conclusion - Overall, Pfizer is positioned to navigate its challenges effectively, with a low stock price and high dividend yield suggesting solid total return potential [16][17]

Pfizer TodayPFEPfizer$23.34 +0.31 (+1.32%) 52-Week Range$20.92▼$31.54Dividend Yield7.37%P/E Ratio16.54Price Target$29.17Add to WatchlistA dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. NYSE: PFE certainly catches the eye of income-seeking investors. Such a substantial return often signals a mature, stable company generously rewarding its shareholders. However, a closer look reveals a complex picture for the New York-based drugmaker. Get Pfizer alerts:Does this impres ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with placebo plus ADT XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with meta ...

Pfizer Inc. ( NYSE: PFE ) is one of the most well-known companies in the pharma sector. This analysis will show that PFE is currently an attractive value play due to its low relativeMy main area of interest is algorithmic trading and trading strategies. However, I am also very interested in macroeconomic topics, especially since I lived and studied in Shanghai for half a year. That is why I plan to write about those topics with a focus on China. I am one semester away from finishing my bachelor's degree in ...

SEONGNAM, South Korea, May 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it the Supreme Court of Korea has ruled in its favor in a patent infringement lawsuit filed by large global pharmaceutical giant Pfizer over its 13-valent pneumococcal conjugate vaccine (PCV13). In 2020, Pfizer claimed that SK bioscience's export of PCV13 individual conjugate bulk substances and research-use finis ...

Group 1 - Pfizer Inc. has revised its oncology pipeline strategy following a co-development deal with Summit Therapeutics in February [2] - The Growth Stock Forum provides a model portfolio of 15-20 stocks, a top picks list of up to 10 stocks, and trading ideas for short-term and medium-term investments [2] Group 2 - The article expresses the author's personal opinions and does not constitute investment advice or recommendations [4] - There is no disclosure of any stock or derivative positions in the companies mentioned, indicating a lack of conflict of interest [3]

Pfizer (PFE) announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from Chinese biotech, 3SBio.3SBio is already developing SSGJ-707 in China for non-small cell lung cancer (“NSCLC”), metastatic colorectal cancer, and gynecological tumors, with the first phase III study expected to begin this year.Unlike the currently available marketed products, which target only the PD-1 protein, SSGJ-707 targets two proteins ...

Pharmaceutical giant Pfizer Inc. (PFE) has signed a significant licensing agreement with China's 3SBio Inc. for an experimental cancer drug, SSGJ-707. According to the deal, Pfizer will pay $1.25 billion upfront and could pay up to an additional $4.8 billion contingent upon achieving certain development milestones. Also, Pfizer plans to invest $100 million in 3SBio through an equity stake once the transaction is finalized, which is expected in third-quarter 2025.For some time now, SSGJ-707 has been undergoi ...

Merck (MRK) and Pfizer (PFE) are leading pharmaceutical companies with strong product and pipeline portfolios in oncology. Both companies also have presences in vaccines, neuroscience, and immunology.However. oncology accounts for more than 50% of Merck’s total revenues. Blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancers, alone accounts for around 50% of its pharmaceutical sales.As regards Pfizer, oncology sales comprise around 25% of its total revenues. Its position in oncology wa ...

Group 1 - Pfizer's share price has increased by 5% over the past month, alleviating investor fears regarding significant changes to vaccination policies for children and older adults [1] - The leadership change with Robert F. Kennedy, Jr. has not led to the anticipated major shifts in vaccination policy [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on identifying undervalued assets in various sectors including pharmaceuticals [1] - The firm aims to simplify investment strategies and empower investors through informed analyses and insights [1]